Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12289221 | 1.00 | PTGER4 (0.50) | PTGER4CYP1A2CYP2D6THRATHRB | |
| SCHEMBL2937605 | 0.96 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL14307440 | 0.96 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2930321 | 0.96 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL14307445 | 0.91 | PTGER4 (0.46) | PTGER4CYP1A2CYP2D6THRATHRB | |
| SCHEMBL2435918 | 0.88 | PTGER4 (0.49) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL12289272 | 0.88 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL12289269 | 0.88 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL3230074 | 0.88 | PTGER4 (0.50) | PTGER4CYP1A2CYP2D6CA2 | |
| SCHEMBL13431496 | 0.88 | PTGER4 (0.50) | PTGER4CYP1A2CYP2D6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| EP-2046742-B1 | BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-2046742-A1 | BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012347-A1 | BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | PTGER4, GPR4, PTGER1 | PTGER4 1/4885CYP1A2 310/4885CYP2D6 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.